At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 607 enrolled
Drug / intervention
Ritlecitinib +1 moredrug
Likely dose
Ritlecitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO
In Brief
A Phase 3 clinical trial evaluating Ritlecitinib and Placebo for Stable Nonsegmental Vitiligo and Active Nonsegmental Vitiligo. Completed, enrolled 607 participants across 115 sites in 15 countries.
Detailed Summary
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Bulgaria, Canada, China, Germany, Italy, Japan, Mexico, Poland, South Africa, South Korea, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartDec 2022
Primary CompletionFeb 2026
TodayJul 2026
First PostedOct 17, 2022
Enrollment StartDec 1, 2022
Primary CompletionFeb 5, 2026
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 3.7 years ago
Interventions
Ritlecitinibdrug
50 mg capsule
Placebodrug
Matching capsule